Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Ryan N. Robb

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7661-7902; OpenAlex author ID A5044479770; NIH RePORTER profile ID 78219452. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
43
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers, 1 grant

Papers 8

  1. High SMAD4 Expression is Associated With Improved Clinical Outcomes in Patients With Resectable Pancreatic Cancer: An Analysis of NRG Oncology/RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2026.09.014↗
  2. Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.06.28.734981↗
  3. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1757↗
  4. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Co-author DOI 10.1158/0008-5472.can-25-1507↗
  5. Nutrient scavenging-fueled growth in pancreatic cancer depends on caveolae-mediated endocytosis under nutrient-deprived conditions. Co-author DOI 10.1126/sciadv.adj3551↗
  6. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic… First author DOI 10.1158/1078-0432.ccr-20-1422↗
  7. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  8. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Co-author DOI 10.18632/oncotarget.27496↗

Grants 1

  1. Mechanistic examination and inhibitor targeting of nutrient scavenging for the treatment of pancreatic cancer F31CA284869↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Terence Marques Williams · 5 shared papers, 2020–2026 · strength 0.73
  2. Kirsten L. Bryant · 3 shared papers, 2025–2026 · strength 0.64
  3. Clint A. Stalnecker · 3 shared papers, 2025–2026 · strength 0.64
  4. Mallory K. Roach · 3 shared papers, 2025–2026 · strength 0.64
  5. Adam R. Wolfe · 4 shared papers, 2020–2024 · strength 0.49
  6. Jonathan M. DeLiberty · 2 shared papers, 2025–2026 · strength 0.45
  7. Mariaelena Pierobon · 2 shared papers, 2025–2026 · strength 0.45
  8. Kristina Drizyte‐Miller · 2 shared papers, 2025 · strength 0.37
  9. Emanuel F. Petricoin · 2 shared papers, 2025 · strength 0.37
  10. Adrienne D. Cox · 2 shared papers, 2025 · strength 0.37
  11. Channing J. Der · 2 shared papers, 2025 · strength 0.37
  12. Hyun Kim · 1 shared paper, 2026 · strength 0.24
  13. Chandan Guha · 1 shared paper, 2026 · strength 0.24
  14. William F. Regine · 1 shared paper, 2026 · strength 0.24
  15. Edgar Ben‐Josef · 1 shared paper, 2026 · strength 0.24
  16. Lauren E. Henke · 1 shared paper, 2026 · strength 0.24
  17. Michael G. Haddock · 1 shared paper, 2026 · strength 0.24
  18. Laith I. Abushahin · 2 shared papers, 2021 · strength 0.23
  19. Nikhil Sebastian · 2 shared papers, 2020–2021 · strength 0.21
  20. Wei Chen · 2 shared papers, 2020–2021 · strength 0.21
  21. Mary E. Dillhoff · 2 shared papers, 2020–2021 · strength 0.21
  22. John P. Morris · 1 shared paper, 2025 · strength 0.19
  23. Sarah E. Ackermann · 1 shared paper, 2025 · strength 0.19
  24. Joanna M. Karasinska · 1 shared paper, 2024 · strength 0.16
  25. Wei Chen · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.